Holen Sie sich die Stockscreener-App
92.59
2.67%
2.41
Handel nachbörslich:
92.37
-0.22
-0.24%
Schlusskurs vom Vortag:
$90.18
Offen:
$91.34
24-Stunden-Volumen:
2.40M
Relative Volume:
1.25
Marktkapitalisierung:
$18.08B
Einnahmen:
$4.58B
Nettoeinkommen (Verlust:
$870.87M
KGV:
21.05
EPS:
4.3988
Netto-Cashflow:
$945.58M
1W Leistung:
+3.67%
1M Leistung:
+10.37%
6M Leistung:
+53.22%
1J Leistung:
+25.24%
1-Tages-Spanne:
$91.19
$94.62
1-Wochen-Bereich:
$84.02
$94.62
52-Wochen-Spanne:
$53.56
$94.62
Incyte Corp Stock (INCY) Company Profile
Firmenname
Incyte Corp
Sektor
Branche
Telefon
(302) 498-6700
Adresse
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Vergleichen Sie INCY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
92.59 | 17.70B | 4.58B | 870.87M | 945.58M | 4.3988 |
|
VRTX
Vertex Pharmaceuticals Inc
|
419.89 | 106.97B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
654.04 | 68.62B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
449.56 | 63.13B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
820.36 | 50.61B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
194.22 | 35.29B | 398.11M | -1.03B | -868.57M | -5.7032 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-08 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2025-08-06 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2025-08-01 | Eingeleitet | Barclays | Overweight |
| 2025-06-16 | Hochstufung | Stifel | Hold → Buy |
| 2025-03-18 | Herabstufung | Guggenheim | Buy → Neutral |
| 2025-03-18 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2024-12-17 | Eingeleitet | UBS | Neutral |
| 2024-10-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2024-10-01 | Eingeleitet | Wolfe Research | Outperform |
| 2024-09-18 | Herabstufung | Truist | Buy → Hold |
| 2024-07-02 | Herabstufung | BMO Capital Markets | Market Perform → Underperform |
| 2024-05-23 | Eingeleitet | Deutsche Bank | Hold |
| 2024-04-23 | Eingeleitet | Cantor Fitzgerald | Neutral |
| 2024-02-23 | Eingeleitet | Jefferies | Buy |
| 2024-02-14 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2023-12-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2023-12-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-11-21 | Herabstufung | Goldman | Buy → Neutral |
| 2023-07-25 | Eingeleitet | Citigroup | Buy |
| 2023-05-04 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-04-10 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2023-03-24 | Hochstufung | SVB Securities | Underperform → Market Perform |
| 2023-01-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-08-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-08-03 | Herabstufung | Guggenheim | Buy → Neutral |
| 2022-07-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-02-09 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2022-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-07-20 | Hochstufung | The Benchmark Company | Hold → Buy |
| 2021-02-10 | Herabstufung | SVB Leerink | Mkt Perform → Underperform |
| 2021-01-07 | Eingeleitet | Truist | Buy |
| 2021-01-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2020-06-16 | Eingeleitet | The Benchmark Company | Hold |
| 2020-05-06 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-04-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-01 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-24 | Fortgesetzt | William Blair | Outperform |
| 2020-03-13 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-04 | Fortgesetzt | BofA/Merrill | Neutral |
| 2020-01-03 | Bestätigt | BMO Capital Markets | Market Perform |
| 2020-01-03 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-01-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-10-03 | Eingeleitet | Mizuho | Buy |
| 2019-09-12 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2019-09-05 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-09-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2019-09-05 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2019-05-21 | Eingeleitet | Credit Suisse | Neutral |
| 2019-05-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2019-04-11 | Eingeleitet | Stifel | Hold |
| 2019-04-03 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-01-24 | Hochstufung | William Blair | Mkt Perform → Outperform |
Alle ansehen
Incyte Corp Aktie (INCY) Neueste Nachrichten
Decoding Incyte Corp (INCY): A Strategic SWOT Insight - GuruFocus
Can Incyte Corporation stock hit record highs againWeekly Trade Review & Expert Verified Stock Movement Alerts - newser.com
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... By GuruFocus - Investing.com Canada
Incyte Corporation (INCY) Stock Forecasts - Yahoo! Finance Canada
Incyte Corp (INCY) Q3 2025 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo! Finance UK
Incyte's (INCY) Hold Rating Reiterated at Truist Financial - MarketBeat
Incyte (INCY) Gains Exclusive Distribution Rights for Tafasitamab in Latin America - GuruFocus
Incyte to Present at Upcoming Investor Conferences - Yahoo Finance
Transcend Capital Advisors LLC Makes New $437,000 Investment in Incyte Corporation $INCY - MarketBeat
Multi asset correlation models including Incyte CorporationMarket Risk Report & Fast Gain Stock Trading Tips - newser.com
Will Incyte Corporation (ICY) stock return to pre crash levels2025 Bull vs Bear & Daily Growth Stock Investment Tips - newser.com
Can Incyte Corporation stock deliver sustainable ROELayoff News & Safe Entry Point Alerts - newser.com
Can Incyte Corporation (ICY) stock attract analyst upgradesOil Prices & Daily Momentum Trading Reports - newser.com
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
RBC Capital Raises Incyte (INCY) Price Target to $84 | INCY Stoc - GuruFocus
Incyte (INCY) Rating Reiterated and Price Target Raised by Truis - GuruFocus
Wells Fargo Raises Incyte (INCY) Price Target to $97.00 | INCY S - GuruFocus
Incyte (INCY): Barclays Raises Price Target to $101 with Overwei - GuruFocus
Incyte Corporation (NASDAQ:INCY) Q3 2025 Earnings Call Transcript - Insider Monkey
Incyte Corporation $INCY Shares Sold by Sumitomo Mitsui Trust Group Inc. - MarketBeat
How Incyte Corporation stock responds to policy changes2025 Valuation Update & Safe Capital Growth Tips - newser.com
INCY Q3 Deep Dive: Strong Product Momentum and Pipeline Reshaping Amid Strategic Refocus - Yahoo! Finance Canada
How Investors Are Reacting To Incyte (INCY) Surging Q3 Earnings and Promising Late-Stage Trial Data - Yahoo! Finance Canada
Incyte: Q3 Earnings Snapshot - Stamford Advocate
Incyte (NASDAQ:INCY) Hits New 12-Month HighWhat's Next? - MarketBeat
Incyte Walloped Third-Quarter Profit Views. Why Shares Fell. - Investor's Business Daily
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte Delivers Robust Growth, But 2028 Patent Expiry Still Looms - Benzinga
1 Growth Stock Under $100 to Buy Before It Soars - Yahoo Finance
Bank of America Securities Maintains a Buy on Incyte Corporation (INCY) - Insider Monkey
Incyte (INCY) Sees Strong Growth with Key Products and Raises Gu - GuruFocus
Why Incyte (INCY) Stock Is Trading Lower Today - Yahoo Finance
Incyte stock price target raised to $109 by BofA on strong Jakafi sales - Investing.com
INCY's Q3 Earnings & Revenues Beat Estimates on Higher Product Sales - TradingView
Incyte Raises Sales Targets But Investors Aren’t Cheering - Finimize
Incyte (INCY) PT Raised to $109 at BofA Securities - StreetInsider
Incyte Q3 2025 slides: Revenue jumps 20% as product portfolio expands - Investing.com
Earnings call transcript: Incyte Q3 2025 beats forecasts, stock surges - Investing.com
Incyte (INCY) Reports Q3 Earnings: What Key Metrics Have to Say - Yahoo Finance
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Incyte Outpaces Expectations And Raises Its Revenue Forecast - Finimize
Incyte (INCY) Boosts 2025 Revenue Forecast on Strong Product Dem - GuruFocus
Incyte Corporation (INCY) Q3 FY2025 earnings call transcript - Yahoo Finance
Incyte Reports Third Quarter 2025 Financial Results and Provides Business Updates - BioSpace
Why Incyte Corporation (ICY) stock stays resilientWeekly Market Report & Growth Focused Stock Pick Reports - newser.com
Incyte Corp (INCY) Q3 2025 Earnings: EPS of $2.11 Beats Estimates, Revenue Surges to $1.37 Billion - GuruFocus
Incyte shares rise as third quarter results beat expectations, guidance raised By Investing.com - Investing.com South Africa
Incyte shares rise as third quarter results beat expectations, guidance raised - Investing.com
Incyte releases new data from Phase IIIb trial of Opzelura in dermatitis - The Pharma Letter
Incyte earnings beat by $0.67, revenue topped estimates - Investing.com
Drugmaker Incyte tops Q3 revenue estimates, raises guidance - TradingView
Finanzdaten der Incyte Corp-Aktie (INCY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):